Compare ASRV & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASRV | ACRV |
|---|---|---|
| Founded | 1983 | 2018 |
| Country | United States | United States |
| Employees | N/A | 78 |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.2M | 47.6M |
| IPO Year | 1994 | 2022 |
| Metric | ASRV | ACRV |
|---|---|---|
| Price | $3.79 | $1.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 19.1K | ★ 729.1K |
| Earning Date | 04-20-2026 | 04-20-2026 |
| Dividend Yield | ★ 3.19% | N/A |
| EPS Growth | N/A | ★ 13.14 |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $15,621,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $805.34 |
| P/E Ratio | $15.00 | ★ N/A |
| Revenue Growth | ★ 7.78 | N/A |
| 52 Week Low | $2.03 | $1.05 |
| 52 Week High | $3.93 | $5.75 |
| Indicator | ASRV | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 60.45 | 41.92 |
| Support Level | $3.01 | $1.51 |
| Resistance Level | $3.91 | $2.47 |
| Average True Range (ATR) | 0.14 | 0.12 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 73.58 | 17.17 |
AmeriServ Financial Inc is a bank holding company. The company and its subsidiaries derive substantially all of their income from banking, bank-related services, and trust-related services. Its operating segment includes community banking and it generates maximum revenue. The community banking segment includes both retail and commercial banking activities. The company also offers retail banking which includes the deposit-gathering branch franchise and lending to both individuals and small businesses; Lending activities include residential mortgage loans, direct consumer loans, and small business commercial loans; Commercial banking to businesses includes commercial loans, business services, and CRE loans.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.